About us

InSCREENeX develops novel engineered mammalian cell systems that speed up drug development (SCREENflex) and enable physiologically relevant tests in vitro under in vivo conditions (CI-SCREEN).

Recombinant stable cell lines for cell-based assays: The SCREENflex technology rapidly (1 month) generates recombinant cell lines expressing your gene of interest (e.g. antibodies, GPCRs, ion channels, kinases) in CHO or HEK293 cells. The cell lines express the target at the desired level (low; medium; high).

Expandable cells with physiologically relevant function: The CI-SCREEN technology generates functionally immortalized cell systems. This enables a drug development in vitro under in vivo like conditions.

It can be applied to any mammalian cell type e.g. to establish cell systems from your desired cell type, pre-clinical disease model, patient-specific cells and disease-specific cells.

Products and services

Products include off-the-shelf (1) engineered expandable mammalian cell systems for science and pharma, e.g., lung epithelial cells, intestinal epithelial cells, endothelial cells; (2) off-the-shelf CHO GPCR cell lines, e.g., ADRB2, CHRM3, HRH2.

Cell line services include (1) rapid generation of recombinant CHO or HEK293 cell lines for cell-based assays (SCREENflex); (2) development of expandable cell systems from any mammalian species for bioassays, drug development and basic research.

Expandable Intestinal Epithelial Cells

Further reading

Optimized Cell Culture Reagents

Further reading

Expandable Hepatocytes

Further reading

Address
InSCREENeX GmbH
Inhoffenstr. 7
38124 Brunswick
Germany

Phone: +49 531 61815080
Internet: www.inscreenex.com
E-mail: Send message

Contact person

Tom Wahlicht
Business Development
E-mail: Send message

Click here if you notice an image that violates copyright or privacy rights.

Get in contact
OK

We use cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection